E-Book | June 9, 2022

Cell Therapy Outsourcing: Current Thinking, Strategies And Trends

Source: Cell & Gene

Outsourced Pharma Chief Editor Louis Garguilo brings readers of Cell & Gene this collection of editorials on the current thinking, strategies, and trends in the cell-therapy space regarding outsourcing, and working with external partners. These editorials are based on interviews with CEOs sharing their analysis and best practices as they play out currently in their companies, and within our global industry. Garguilo covers Europe from the perspective of Miguel Forte, CEO, Bone Therapeutics, a most respected entrepreneur (MD, and professor) in the cell-therapy industry there. In the U.S., 30-year industry veteran and current CEO of Triumvira Immunologics, Paul Lammers, details an intriguing relationship his biopharma has with CDMOs, and shares his view on aspects of autologous and allogeneic therapies.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene